Core Viewpoint - Rongchang Biopharma (09995) reported a significant increase in revenue and profit for the fiscal year 2025, driven by strong sales of its injectable products and a notable rise in technology licensing income [1] Financial Performance - The company achieved total revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36% [1] - Net profit attributable to the parent company was RMB 709 million, marking a turnaround from a loss to profitability [1] - Basic earnings per share reached RMB 1.29 [1] Revenue Drivers - The increase in revenue was primarily due to higher sales of injectable products, specifically Tai Taisip and Vidisitamab [1] - The company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Tai Taisip outside Greater China, leading to a substantial increase in technology licensing income [1] Margin and Expenses Outlook - Nomura's report predicts that the company's gross margin will rise by 5.4 percentage points year-on-year to 94.4%, benefiting from improved drug margins and a higher proportion of high-margin collaborative income [1] - Operating expenses are expected to increase by 28% year-on-year to RMB 3.5 billion due to a significant rise in cash reserves, reversing last year's cost-saving trend [1] - Research and development expenses and sales costs are projected to be RMB 1.6 billion each, aimed at sponsoring new molecular research and clinical trials, as well as enhancing drug sales [1]

Core Viewpoint - The healthcare index (980016) experienced a rise of 1.01% on March 5, closing at 5804.4 points, with a total transaction volume of 9.822 billion yuan and a turnover rate of 0.35% [1] Group 1: Index Performance - On the same day, 36 constituent stocks of the healthcare index increased in value, with Rongchang Biological leading the gains at 4.86% [1] - Conversely, 12 stocks declined, with Ailis leading the losses at 3.61% [1] Group 2: Capital Flow - The net outflow of main funds from the healthcare index constituents totaled 229 million yuan, while retail funds saw a net outflow of 61.5482 million yuan [2] - In contrast, there was a net inflow of 290 million yuan from speculative funds [2]

Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company based in Yantai, Shandong, China, established on July 4, 2008, and listed on March 31, 2022 [1] - The company focuses on the development and commercialization of therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [1] - The main revenue sources are from product sales (99.46%), material sales (0.38%), and leasing services (0.16%) [1] Stock Performance - On March 5, Rongchang Biopharmaceuticals' stock rose by 5.04%, reaching a price of 93.16 CNY per share, with a trading volume of 252 million CNY and a turnover rate of 1.70%, resulting in a total market capitalization of 52.587 billion CNY [1] Fund Holdings - Penghua Fund has a significant holding in Rongchang Biopharmaceuticals, with its Penghua SSE STAR Market Biomedicine ETF (588250) increasing its position by 7,625 shares in the fourth quarter, totaling 76,900 shares, which represents 2.85% of the fund's net value [2] - The ETF has a current size of 210 million CNY and has experienced a year-to-date loss of 7.09%, ranking 5242 out of 5570 in its category [2] Fund Management - The fund manager of the Penghua SSE STAR Market Biomedicine ETF is Lin Song, who has been in the position for 2 years and 250 days, managing total assets of 3.741 billion CNY [3] - During Lin Song's tenure, the best fund return was 43.89%, while the worst return was -22.7% [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 榮昌生物製藥（煙台）股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09995 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 208,581,239 | RMB | | 1 | RMB | | 208,581,239 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 208,581,239 | RMB | | 1 | RMB | | 208,581,239 | | 2. 股份分類 ...

Core Insights - Rongchang Biologics reported a significant increase in revenue for 2025, reaching 3.25 billion yuan, a year-on-year increase of 89.36%, and achieved a net profit of 710 million yuan, reversing a loss of 1.468 billion yuan in 2024 [1][9] - The company's revenue growth was primarily driven by increased domestic sales of its core products, Taitasip and Vidisitamab, which became the main growth engines for its performance [10][11] Financial Performance - The net profit of 710 million yuan indicates a successful turnaround from the previous year's loss, showcasing the company's improved financial health [1][9] - After excluding non-recurring gains, the adjusted net profit for 2025 was 65.05 million yuan, indicating operational profitability driven solely by domestic sales of Taitasip and Vidisitamab [3][12] Product Development - Vidisitamab (RC48) is China's first independently developed ADC drug, currently approved for gastric cancer, urothelial carcinoma, and breast cancer with liver metastasis [4][13] - Taitasip (RC18) is a globally innovative drug targeting dual pathways (BLyS/APRIL), approved for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis, with potential in other conditions [4][13] Strategic Partnerships - The company secured a significant collaboration by licensing Taitasip to Vor Bio for $1.25 billion, including a $450 million upfront payment and potential milestone payments totaling up to $4.105 billion, setting a record for autoimmune drug licensing in China [7][16] - In another deal, Rongchang Biologics licensed RC28-E to Santen Pharmaceutical for a total of 2.5 billion yuan in upfront and milestone payments [7][16] Research Pipeline - The company is advancing its pipeline with RC148, a bispecific antibody targeting PD-1/VEGF, which has entered Phase 3 clinical trials for squamous non-small cell lung cancer [5][14] - Other promising candidates include RC28-E, RC278, RC118, and RC288, targeting various cancers and diseases, indicating a robust development strategy [5][14] Conclusion - 2025 is a pivotal year for Rongchang Biologics, as it successfully crossed the breakeven point financially and established significant international partnerships, validating the clinical and commercial potential of its innovative drugs [8][18]

Group 1 - The company Rongchang Bio (09995.HK) reported a total revenue of approximately 3.251 billion RMB for 2025, representing a year-on-year increase of 89.36% [1] - The net profit attributable to the parent company's owners is approximately 709 million RMB, a significant recovery from a loss of about 1.468 billion RMB in the same period of 2024 [1] - The basic earnings per share is reported at 1.29 RMB [1]

Core Viewpoint - Rongchang Biopharma reported a significant increase in revenue and profit for the fiscal year 2025, indicating a strong performance driven by key product sales and strategic partnerships [1] Financial Performance - The company achieved total operating revenue of 3.251 billion yuan, representing a year-on-year increase of 89.36% [1] - The net profit attributable to shareholders reached 709 million yuan, marking a turnaround from previous losses to profitability [1] Growth Drivers - The rapid growth in domestic sales of core products, Tai Tasi Pu and Vidi Xi Tuo Dan Kang, has become the main growth engine for the company's performance [1] - A significant licensing agreement with Vor Biopharma has led to a substantial increase in technology licensing revenue [1] Operational Efficiency - The company has improved its profitability efficiency through management optimization and process iteration, resulting in reduced unit costs and increased gross margins [1] - The sales expense ratio has also decreased significantly, contributing to the overall improvement in profitability [1]

Core Viewpoint - Rongchang Biopharma (688331) reported a significant increase in revenue and profitability for the year 2025, indicating a strong turnaround and growth potential in its core products and strategic partnerships [2][4]. Financial Performance - The company achieved an operating revenue of 3.251 billion yuan, representing a year-on-year growth of 89.36% [2]. - The net profit attributable to shareholders was 709 million yuan, marking a turnaround from a loss in the previous year [2]. - The non-deductible net profit was 65.06 million yuan, compared to a loss in the same period last year [2]. - Basic earnings per share were 1.29 yuan, with a weighted average return on equity of 24.88%, an increase of 78.95 percentage points from the previous year [7]. Valuation Metrics - As of the close on February 27, the company's price-to-earnings (P/E) ratio (TTM) was approximately 78.61, the price-to-book (P/B) ratio (LF) was about 23.85, and the price-to-sales (P/S) ratio (TTM) was around 25 [2]. Growth Drivers - The core products, Taitasip and Vedisitomab, saw rapid growth in domestic sales, becoming the main drivers of the company's performance [4]. - The company secured a significant partnership with Vor Biopharma Inc., granting exclusive global development and commercialization rights for Taitasip outside Greater China, leading to a substantial increase in technology licensing revenue [4]. - Management optimization and production process improvements contributed to reduced unit production costs and increased gross margins, alongside a notable decrease in sales expense ratios [4].

Core Viewpoint - Rongchang Biopharmaceutical (Yantai) Co., Ltd. has announced a change in its signing registered accountant for the 2025 fiscal year, with the appointment of Zhu Wenyang to replace Wang Min, who has resigned [2][6]. Group 1: Change of Signing Registered Accountant - The company has reappointed Ernst & Young Huaming as its domestic audit firm and Ernst & Young as its overseas audit firm for the 2025 fiscal year [2]. - Zhu Wenyang, who became a registered accountant in 2022 and has been with Ernst & Young Huaming since 2021, will now serve as the signing accountant alongside Yang Jing [3][6]. Group 2: Financial Performance Overview - For the fiscal year 2025, the company reported a revenue of RMB 325,105.11 million, representing a year-on-year increase of 89.36% [10]. - The net profit attributable to the parent company reached RMB 70,852.33 million, with a significant improvement in profitability due to increased sales of core products and successful collaborations [10][11]. - Total assets grew by 31.65% to RMB 723,868.50 million, while equity attributable to the parent company increased by 81.40% to RMB 360,304.78 million [10][12]. Group 3: Factors Influencing Financial Performance - The increase in revenue was primarily driven by higher sales of the injectable drugs Tai'ta Xip and Vidi Xitomab, as well as substantial technology licensing income from Vor Biopharma Inc. [11]. - The company has improved its profitability through cost management and a reduction in sales expense ratios, leading to a significant enhancement in profit margins [10][11].

格隆汇2月27日丨荣昌生物(688331.SH)公布2025年度业绩快报，报告期内，公司实现营业收入32.51亿 元，同比增加89.36%；实现归属于母公司所有者的净利润7.09亿元；实现归属于母公司所有者的扣除非 经常性损益的净利润6505.64万元。 ...